Compare DexCom, Inc. (DXCM) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Jabil Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Jabil Inc trades at $306.28 (market cap $31.35B). The key difference: DexCom, Inc. and Jabil Inc are close in size by market cap, and Jabil Inc pays a 0.11% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Jabil Inc for 23 Days on average.
| DXCM | JBL | |
|---|---|---|
Market Cap | $31.86B | $31.35B |
Volume | 3,607,070 | 1,337,978 |
Sector | Health | Technology |
52-Week High | $92.34 | $385.50 |
52-Week Low | $54.84 | $192.49 |
Typical Hold Time | 62 Days | 23 Days |
Enterprise Value | $31.32B | $33.63B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
JBL trades at $299.16, down 0.1% on the day, amid a bearish technical signal despite strong Q4 2026 earnings that beat estimates with EPS of $4.40. The stock shows robust fundamentals, including 74.11% ROE and a consensus analyst price target of $434.75, implying significant upside. Recent news highlights AI infrastructure demand driving growth, with fiscal 2027 revenue growth projected at 24%.
The outlook is positive due to accelerating AI demand and strong earnings momentum, but risks include high valuation multiples and market volatility. Analyst consensus is strongly bullish with no sell ratings, supporting a long-term growth narrative despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
